Gilead's lenacapavir demonstrates long-term efficacy against HIV
Justin Sullivan/Getty Images News


Data from a phase 3 study on Gilead Sciences' (GILD
+0.8%) lenacapavir given subcutaneously every six months in combination with other antiretrovirals led to high rates of virologic suppression over one year for treatment of HIV.
In the trial, the long-acting HIV-1 capsid inhibitor was given to heavily treated HIV patients who had failed on other medicines.

Results also showed that there were clinically meaningful increases in CD4 counts.
In the population, 83% of those receiving lenacapavir in combination other medications achieved an undetectable viral load at week 52.
The data was presented 29th Conference on Retroviruses and Opportunistic Infections (virtual CROI 2022).
Gilead (GILD
+0.8%) presented 26-week data on lenacapavir in March 2021.